Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Japan Launches Four New Products

This article was originally published in PharmAsia News

Executive Summary

Swiss drug maker Novartis' Japanese subsidiary, Novartis Pharma K.K. launched four products in the Japanese market March 13. The new drugs are Xolair, Co-Dio, Tasigna and Lucentis. The first asthma antibody drug approved in Japan, Xolair (omalizumab), is used to treat severe asthma that can not be controlled by other drugs and is administrated every other week or every four weeks. Co-Dio is a hypertension combo drug of valsartan and hydrochlorothiazide. Tasigna (nilotinib) is indicated for adult chronic myelogenous leukemia patients resistant or intolerant to prior therapy. Antibody drug Lucentis (ranibizumab) treats age-related macular degeneration. The four products were approved in Japan in January. (Click here for more - Japanese language
Advertisement
Advertisement
UsernamePublicRestriction

Register

SC071083

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel